07/11/19 -"We have made some adjustments to take into account the huge impairment and added some first costs (€120m for 2019-21) in the implementation of the €300-350m cost reduction plan to our P&L. "
Pages
60
Language
English
Published on
07/11/19
You may also be interested by these reports :
22/10/26
Yara’s Q3 2026 revenue growth was entirely price-driven. Higher gas costs outweighed price gains and squeezed earnings. Management responded with ...
21/10/26
AkzoNobel’s Q3 2026 sales were driven by pricing rather than demand: volumes fell again and full-year volume guidance was trimmed. Margins edged up ...
14/10/26
2026E: We raise our H2 2026 estimates, with our view that earnings will be driven primarily by pricing. We expect Q3 to broadly replicate Q2 2026, ...
13/10/26
Givaudan delivered a strong quarter, reaffirming its leading position in fragrances. Fine Fragrance continues to resist the normalisation anticipated ...